Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)

Daniel,Soliman,Eman,Griffin,LaToya,Van Dross,Rukiyah Ladin (Creator)

Institution

East Carolina University (ECU )

Web Site: http://www.ecu.edu/lib/

Abstract: Cancer is the second leading cause of death in the United States with 1.7 millionnew cases estimated to be diagnosed in 2016. This disease remains a formidableclinical challenge and represents a substantial financial burden to the US health caresystem. Therefore, research and development of novel therapeutics for the treatmentof cancer is of high priority. Cannabinoids and their derivatives have been utilized fortheir medicinal and therapeutic properties throughout history. Cannabinoid activity isregulated by the endocannabinoid system (ECS), which is comprised of cannabinoidreceptors, transporters, and enzymes involved in cannabinoid synthesis and breakdown.More recently, cannabinoids have gained special attention for their role in cancer cellproliferation and death. However, many studies investigated these effects using in vitromodels which may not adequately mimic tumor growth and metastasis. As such, thisarticle aims to review study results which evaluated effects of cannabinoids from plant,synthetic and endogenous origins on cancer development in preclinical animal modelsand to examine the current standing of cannabinoids that are being tested in humancancer patients.

Additional Information

Publication

Other

Language: English

Date: 2016

Keywords

cannabinoids, cancer, in vivo, clinical studies, clinical trials, therapeutics, cancer models, endocannabinoids

Email this document to